BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5520
- TODAY'S CHANGE (%)-0.0080 (-1.4286%)
- Bid / Lots0.5519/ 1
- Ask / Lots0.5599/ 25
- Open / Previous Close0.5600 / 0.5600
- Day Range
- 52 Week Range
- Volume48,713
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 2050 | 0.56 |
| 09:43 ET | 3303 | 0.56 |
| 09:45 ET | 891 | 0.5665 |
| 09:48 ET | 8999 | 0.553 |
| 09:50 ET | 112 | 0.572799 |
| 09:56 ET | 500 | 0.56755 |
| 10:14 ET | 175 | 0.566349 |
| 10:24 ET | 100 | 0.5664 |
| 10:26 ET | 1825 | 0.56 |
| 10:30 ET | 419 | 0.565 |
| 10:33 ET | 3817 | 0.5525 |
| 10:42 ET | 480 | 0.5527 |
| 11:13 ET | 170 | 0.558447 |
| 11:15 ET | 100 | 0.56 |
| 11:22 ET | 23770 | 0.5519 |
| 11:29 ET | 1250 | 0.552 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 48.8M | -0.7x | --- |
Cue Biopharma Inc | 49.6M | -1.0x | --- |
Marker Therapeutics Inc | 48.1M | -3.9x | --- |
LAVA Therapeutics NV | 49.2M | -1.8x | --- |
Dyadic International Inc | 44.7M | -5.5x | --- |
Palatin Technologies Inc | 30.0M | -0.8x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.8M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 4.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
